Receives $2 Million Non-Refundable Option Fee For Due Diligence Period

GAITHERSBURG, Md. (October 14, 2011) – Cytomedix, Inc. (OTC/BB: CMXI) (the “Company”), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, announced today the execution of a letter agreement granting an undisclosed global pharmaceutical company an exclusivity period until December 31, 2011 to conduct further due diligence regarding the AutoloGel™ System. In exchange, Cytomedix will receive a $2 million non-refundable option fee within 15 days.

The parties are negotiating an exclusive license and supply agreement whereby the AutoloGel System would be distributed through a dedicated, hospital-based sales force. Any final agreement, which remains subject to the successful conclusion of due diligence and negotiation between the parties, is expected to incorporate an upfront license payment, a product development milestone payment covering the second generation AutoloGel device, and a negotiated profit sharing arrangement on future U.S. based sales of the AutoloGel System in the chronic wound care market.

“We are very pleased to be approaching a key milestone in the broad commercialization of the AutoloGel System. Over the next several weeks, we will be focused on pursuing a robust agreement that delivers value to our shareholders while advancing our long standing commitment to have this therapy appropriately positioned and more widely marketed in the underserved chronic wound care market. We will have no further comment on the specifics of this potential transaction until a definitive agreement

http://www.cytomedix.com/investors/archive/bid/83400/CYTOMEDIX-ANNOUNCES-OPTION-AGREEMENT-WITH-GLOBAL-PHARMACEUTICAL-COMPANY-FOR-DISTRIBUTION-OF-AUTOLOGEL-SYSTEM-IN-CHRONIC-WOUND-MARKET